Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Cancer Causes & Control
Published in: Cancer Causes & Control 1/2013

01-01-2013 | Original paper

Comorbidities and endometrial cancer survival in Hispanics and non-Hispanic whites

Authors: Linda S. Cook, Harold E. Nelson, Myles Cockburn, Sara H. Olson, Carolyn Y. Muller, Charles L. Wiggins

Published in: Cancer Causes & Control | Issue 1/2013

Login to get access

Abstract

Purpose

We investigated comorbidities and endometrial cancer survival by ethnicity because Hispanic whites (HWs) have worse survival than non-Hispanic whites (NHWs).

Methods

An endometrial cancer cohort (1992–2004) established with the Surveillance, Epidemiology and End Results-Medicare-linked database (n = 3,286) was followed through 2007. Endometrial cancer-specific and other cause mortality were evaluated with multivariate hazard ratios (mHRs).

Results

HWs were more likely than NHWs to have regional/distant disease (31.7 vs. 24.8 %), diabetes (31.7 vs. 11.0 %), and hypertension (49.4 vs. 37.6 %). HWs had poorer endometrial cancer-specific survival than NHWs (age-adjusted HR = 1.28; 95% CI 1.01–1.61), but not after adjustment for tumor characteristics and treatment (mHR = 1.02; 95% CI 0.81–1.29). In contrast, even after adjustment for cancer-related factors, other cause mortality in HWs was elevated (mHR = 1.27; 95% CI 1.01–1.59), but not after further adjustment for comorbid conditions (mHR = 1.07; 95% CI 0.85–1.35).

Conclusions

Comorbidities, particularly diabetes, were more common in HWs than in NHWs and impacted other cause mortality. Improving diabetes management may be an effective means of improving other cause mortality. This may be particularly true for HWs, given their particularly high prevalence of diabetes.
Appendix
Available only for authorised users
Literature
1.
Sarcoma Uterine (2008) In: Schorge JO, Schaffer JI, Halvorson LM et al (eds) Williams gynecology. McGraw-Hill Companies, New York, pp 706–715
2.
Cancer Endometrial (2008) In: Schorge JO, Schaffer JI, Halvorson LM et al (eds) Williams gynecology. McGraw-Hill Companies, New York, pp 687–705
3.
Sherman ME, Devesa SS (2003) Analysis of racial differences in incidence, survival, and mortality for malignant tumors of the uterine corpus. Cancer 98(1):176–186PubMedCrossRef
4.
Creasman WT, Morrow CP, Bundy BN, Homesley HD, Graham JE, Heller PB (1987) Surgical pathologic spread patterns of endometrial cancer: a Gynecologic Oncology Group Study. Cancer 60:2035–2041PubMedCrossRef
5.
Cook LS, Kmet LM, Magliocco AM, Weiss NS (2006) Endometrial cancer survival among US black and white women by birth cohort. Epidemiology 17(4):469–472PubMedCrossRef
6.
Olson SH, Atoria C, Cote ML, et al. (2012) The impact of race and comorbidity on survival in endometrial cancer. Cancer Epidemiol Biomarkers Prev 00: 00–00 (in press)
7.
Centers for Disease Control and Prevention (2004) Prevalence of diabetes among Hispanics, selected areas, 1998–2002. MMWR 53(40):941–944
8.
Borrell LN (2006) Self-reported hypertension and race among Hispanics in the National Health Interview Survey. Ethn Dis 16(1):71–77PubMed
9.
Braithwaite D, Tammemagi CM, Moore DH et al (2009) Hypertension is an independent predictor of survival disparity between African-American and white breast cancer patients. Int J Cancer 124(5):1213–1219PubMedCrossRef
10.
Folsom AR, Anderson KE, Sweeney C, Jacobs DR Jr (2004) Diabetes as a risk factor for death following endometrial cancer. Gynecol Oncol 94(3):740–745PubMedCrossRef
11.
Chia VM, Newcomb PA, Trentham-Dietz A, Hampton JM (2007) Obesity, diabetes, and other factors in relation to survival after endometrial cancer diagnosis. Int J Gynecol Cancer 17(2):441–446PubMedCrossRef
12.
Steiner E, Plata K, Interthal C et al (2007) Diabetes mellitus is a multivariate independent prognostic factor in endometrial carcinoma: a clinicopathologic study on 313 patients. Eur J Gynaecol Oncol 28(2):95–97PubMed
13.
Kauppila A, Gronroos M, Nieminen U (1982) Clinical outcome in endometrial cancer. Obstet Gynecol 60(4):473–480PubMed
14.
Cook LS, Weiss NS, Doherty J, Chen C (2006) Endometrium. In: Schottenfeld Fraumeni (ed) Cancer epidemiology and prevention, 3rd edn. Oxford University Press, New York
15.
Weiderpass E, Persson I, Adami HO, Magnusson C, Lindgren A, Baron JA (2000) Body size in different periods of life, diabetes mellitus, hypertension, and risk of postmenopausal endometrial cancer (Sweden). Cancer Causes Control 11(2):185–192PubMedCrossRef
16.
Lucenteforte E, Bosetti C, Talamini R et al (2007) Diabetes and endometrial cancer: effect modification by body weight, physical activity and hypertension. Br J Cancer 97(7):995–998PubMedCrossRef
17.
Friberg E, Mantzoros CS, Wolk A (2007) Diabetes and risk of endometrial cancer: a population-based prospective cohort study. Cancer Epidemiol Biomarkers Prev 16(2):276–280PubMedCrossRef
18.
19.
Hankey BF, Ries LA, Edwards BK (1999) The surveillance, epidemiology, and end results program: a national resource. Cancer Epidemiol Biomarkers Prev 8(12):1117–1121PubMed
20.
21.
Bach PB, Guadagnoli E, Schrag D, Schussler N, Warren JL (2002) Patient demographic and socioeconomic characteristics in the SEER-Medicare database applications and limitations. Med Care 40(8 Suppl): IV-25
22.
Fritz A, Percy C, Jack A, Shanmugaratnam K, Sobin L, Parkin DM, Whelan S (eds) (2000) International classification of diseases for oncology, 3rd edn. World Health Organization, Geneva, Switzerland
23.
Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40(5):373–383PubMedCrossRef
24.
Deyo RA, Cherkin DC, Ciol MA (1992) Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 45(6):613–619PubMedCrossRef
25.
Romano PS, Roos LL, Jollis JG (1993) Adapting a clinical comorbidity index for use with ICD-9-CM administrative data: differing perspectives. J Clin Epidemiol 46(10):1075–1079PubMedCrossRef
26.
27.
Hebert PL, Yawn BP, McBean AM (1988) Identifying rural elderly individuals with diabetes mellitus using Medicare claims data. University of Minnesota Rural Health Research Center Working Paper
28.
International Classification of Diseases (ICD)-9-CM for Hospitals (2011) Ninth edition. American Medical Association and Elsevier Saunders, St Louis, Missouri Vol. 1, 2, and 3
29.
Klabunde CN, Legler JM, Warren JL, Baldwin LM, Schrag D (2007) A refined comorbidity measurement algorithm for claims-based studies of breast, prostate, colorectal, and lung cancer patients. Ann Epidemiol 17(8):584–590PubMedCrossRef
30.
Young JL (2000) SEER summary staging manual 2000: codes and coding instructions. NIH Publication No. 01-4969, Bethesda, MD
31.
Elandt-Johnson RC, Johnson NL (1980) Survival models and data analysis. Wiley, New York
32.
Howlader N, Ries LAG, Mariotto AB et al (2010) Improved estimates of cancer-specific survival rates from population-based data. J Natl Cancer Inst 102:1584–1598PubMedCrossRef
33.
Gold R, Michael YL, Whitlock EP et al (2006) Race/ethnicity, socioeconomic status, and lifetime morbidity burden in the women’s health initiative: a cross-sectional analysis. J Womens Health (Larchmt) 15(10):1161–1173CrossRef
34.
Tucker-Seeley RD, Li Y, Sorensen G, Subramanian SV (2011) Lifecourse socioeconomic circumstances and multimorbidity among older adults. BMC Public Health 11:313PubMedCrossRef
35.
Lawlor DA, Davey SG, Patel R, Ebrahim S (2005) Life-course socioeconomic position, area deprivation, and coronary heart disease: findings from the British Women’s Heart and Health Study. Am J Public Health 95(1):91–97PubMedCrossRef
36.
Diaz-Montes TP, Alberg A, Zahurak ML, Trimble EL, Bristow RE (2005) Cancer of the uterine corpus among Hispanic women living in the United States: patterns of staging, diagnosis, and primary treatment. Gynecol Oncol 96(3):753–759PubMedCrossRef
37.
Trimble EL, Harlan LC, Clegg LX, Stevens JL (2005) Pre-operative imaging, surgery and adjuvant therapy for women diagnosed with cancer of the corpus uteri in community practice in the United States. Gynecol Oncol 96(3):741–748PubMedCrossRef
38.
Allard JE, Maxwell GL (2009) Race disparities between black and white women in the incidence, treatment, and prognosis of endometrial cancer. Cancer Control 16(1):53–56PubMed
39.
Clegg LX, Reichman ME, Hankey BF et al (2007) Quality of race, Hispanic ethnicity, and immigrant status in population-based cancer registry data: implications for health disparity studies. Cancer Causes Control 18(2):177–187PubMedCrossRef
40.
Crosbie EJ, Roberts C, Qian W, Swart AM, Kitchener HC, Renehan AG (2011) Body mass index does not influence post-treatment survival in early stage endometrial cancer: results from the MRC ASTEC trial. Eur J Cancer 48(6):853–864PubMedCrossRef
41.
Jeong NH, Lee JM, Lee JK et al (2010) Role of body mass index as a risk and prognostic factor of endometrioid uterine cancer in Korean women. Gynecol Oncol 118(1):24–28PubMedCrossRef
42.
Cowie CC, Rust KF, Byrd-Holt DD et al (2006) Prevalence of diabetes and impaired fasting glucose in adults in the US population: National Health and Nutrition Examination Survey 1999–2002. Diabetes Care 29(6):1263–1268PubMedCrossRef
43.
Papanas N, Giatromanolaki A, Galazios G, Maltezos E, Sivridis E (2006) Endometrial carcinoma and diabetes revisited. Eur J Gynaecol Oncol 27(5):505–508PubMed
Metadata
Title
Comorbidities and endometrial cancer survival in Hispanics and non-Hispanic whites
Authors
Linda S. Cook
Harold E. Nelson
Myles Cockburn
Sara H. Olson
Carolyn Y. Muller
Charles L. Wiggins
Publication date
01-01-2013
Publisher
Springer Netherlands
Published in
Cancer Causes & Control / Issue 1/2013
Print ISSN: 0957-5243
Electronic ISSN: 1573-7225
DOI
https://doi.org/10.1007/s10552-012-0090-z

Other articles of this Issue 1/2013

Cancer Causes & Control 1/2013 Go to the issue

Original paper

Prospective cohort study of metabolic risk factors and gastric adenocarcinoma risk in the Metabolic Syndrome and Cancer Project (Me-Can)

Original paper

The association between cancer and amyotrophic lateral sclerosis

Original Paper

Incidence of cancer in Iranian sulfur mustard exposed veterans: a long-term follow-up cohort study

Original paper

A multi-ethnic breast cancer case–control study in New Zealand: evidence of differential risk patterns

Original paper

CYP2C9 variants increase risk of colorectal adenoma recurrence and modify associations with smoking but not aspirin treatment

Original paper

Insulin-like growth factors (IGFs) and IGF-binding proteins in active monitoring of localized prostate cancer: a population-based observational study
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits